Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(R)-2HG competitively inhibited BCAT1, which is a cytosolic enzyme, with respect to 2OG over a physiologically-relevant range of 2OG concentrations”
From Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) · cites this paper as Koivunen et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“Though it is found at low levels in normal cells, D-2HG can accumulate to millimolar levels in cancer cells expressing mutant IDH. At these high concentrations, D-2HG can inhibit αKG-dependent dioxygenases, including enzymes involved in histone and DNA demethylation (Chowdhury et al., 2011; Janke et al., 2017; Koivunen et al., 2012; Xu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Koivunen et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cell”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradatio”
BackgroundIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373 · cited 1×
“Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlie”
MethodAbsolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli
Bennett, B. D., Kimball, E. H., Gao, M., Osterhout, R., Van Dien, S. J., & Rabinowitz, J. D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.186 · Cited by 1,830 · cited 1×
“Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m value”
BackgroundGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brai”
ResultThe oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Cited by
Items 201–300 of 752
Zeng, L., Morinibu, A., Kobayashi, M., Zhu, Y., Wang, X., Gotö, Y., Yeom, C. J., Zhao, T., Hirota, K., Shinomiya, K., et al. (2014) · Oncogene · doi:10.1038/onc.2014.411 · Cited by 109
The TCA cycle as a bridge between oncometabolism and DNA transactions in cancer
Ciccarone, F., Vegliante, R., Leo, L. D., & Ciriolo, M. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.008 · Cited by 100
Davis, M. I., Gross, S., Shen, M., Straley, K. S., Pragani, R., Lea, W. A., Popovici-Muller, J., DeLaBarre, B., Artin, E., Thorne, N., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511030 · Cited by 91
“R172K) (7), and acts as an inhibitor of the -KG-dependent epigenetic machinery (8, 9), blocking differentiation and promoting the proliferation of undifferentiated tumorous cells.”
Zhang, L., Sørensen, M. D., Kristensen, B. W., Reifenberger, G., McIntyre, T. M., & Lin, F. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3855 · Cited by 95
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
Cruz, J. V. R., Batista, C., Afonso, B. D. H., Alexandre‐Moreira, M. S., Dubois, L. G., Pontes, B., Moura‐Neto, V., & Mendes, F. A. (2022) · Cancers · doi:10.3390/cancers14133203 · Cited by 104
Reitman, Z. J., Duncan, C. G., Poteet, E., Winters, A., Yan, L.-J., Gooden, D. M., Spasojevic, I., Boros, L. G., Yang, S.-H., & Yan, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.575183 · Cited by 86
“Cell Culture—HCT116 sublines described previously (23), were cultured in McCoy’s 5A media (Invitrogen, Cat.”
MethodSelf-citationNatsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Hollinshead, K. E. R., Munford, H., Eales, K. L., Bardella, C., Li, C., Escribano-Gonzalez, C., Thakker, A., Nonnenmacher, Y., Kľučková, K., Jeeves, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.084 · Cited by 103
“It is important to note that the 2HG produced by mutant IDH1 may interfere with cell survival and proliferation in hypoxia by inhibiting the stabilization of the transcription factor, hypoxia inducible factor 1 (HIF1) (Koivunen et al., 2012; Tarhonskaya et al., 2014).”
The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer
Zhao, X., Fu, J., Du, J., & Xu, W. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41051 · Cited by 90
“D-2HG can competitively restrain α-KG-dependent dioxygenase enzymes, including DNA and histone demethylases [51-55].”
BackgroundTietze, A., Choi, C., Mickey, B., Maher, E. A., Ulhøi, B. P., Sangill, R., Lassen–Ramshad, Y., Lukacova, S., Østergaard, L., & von Öettingen, G. (2017) · Journal of neurosurgery · doi:10.3171/2016.10.jns161793 · Cited by 97
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
Akbay, E. A., Moslehi, J., Christensen, C. L., Saha, S., Tchaicha, J. H., Ramkissoon, S. H., Stewart, K. M., Carretero, J., Kikuchi, E., Zhang, H., et al. (2014) · Genes & Development · doi:10.1101/gad.231233.113 · Cited by 87
Self-citationSadiku, P., Willson, J. A., Dickinson, R. S., Murphy, F., Harris, A. J., Lewis, A., Sammut, D., Mirchandani, A. S., Ryan, E., Watts, E. R., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90848 · Cited by 87
Recent advances of IDH1 mutant inhibitor in cancer therapy
Tian, W., Zhang, W., Wang, Y., Jin, R., Wang, Y., Guo, H., Tang, Y., & Yao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.982424 · Cited by 93
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 92
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 86
“This is associated with enhanced degradation of HIF-α subunits in cell lines expressing IDH1 mutations, and with blunted expression of HIF target genes in IDH1/2-mutant gliomas [36].”
BackgroundD2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2
Lin, A.-P., Abbas, S., Kim, S.-W., Ortega, M., Bouamar, H., Escobedo, Y., Varadarajan, P., Qin, Y., Sudderth, J., Schulz, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms8768 · Cited by 86
van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88
“141,142 Multiple IDH inhibitors have been developed, some specific for mutant IDH1, while others inhibit both mutant IDH1 and IDH2.”
BackgroundIDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Kayabölen, A., Yilmaz, E., & Onder, T. B. (2021) · Biomedicines · doi:10.3390/biomedicines9070799 · Cited by 97
“Along these lines, it was later shown that D-2-HG, but not L-2-HG, induces the activity of HIF prolyl hydroxylases (EGLN) more than 2-OG itself, resulting in increased HIF-1α degradation [95].”
BackgroundD-2-Hydroxyglutarate in Glioma Biology
Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 95
“In IDH1/2mut glioma cell lines, Zhao et al. described that a high concentration of D-2-HG suppresses the activity of PHDs and FIHs, which reduces HIF-1α degradation, and increases HIF-1-dependent transcription [87].”
BackgroundInfluentialIncreased Expression of PHGDH and Prognostic Significance in Colorectal Cancer
Jia, X.-Q., Zhang, S., Zhu, H., Wang, W., Zhu, J., Wang, X., & Qiang, J. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.03.006 · Cited by 91
Metabolite sensing and signaling in cancer
Wang, Y.-P., Li, J., Qu, J., Yin, M., & Lei, Q. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.007624 · Cited by 104
“Furthermore, 2HG activates EGL-nine (EGLN) prolyl hydroxylase, which mediates the degradation of hypoxia-inducible factor (HIF), thereby promoting the transformation of brain tumors expressingmutant IDH (21).”
BackgroundInfluentialR-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis
Ye, D., Ma, S., Xiong, Y., & Guan, K.-L. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.005 · Cited by 83
“Both enantiomers inhibit many a-KG-dependent dioxygenases, with R-2-HG being significantly less potent than S-2-HG (Chowdhury et al., 2011; Xu et al., 2011; Koivunen et al., 2012).”
BackgroundReconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 88
“IDH dysregulation likely contributes to gliomagenesis via the accumulation of the oncogenic metabolite R(−)-2hydroxyglutarate (2HG) [114, 176].”
BackgroundSelf-citationMetabolic tricks of cancer cells
Hönigová, K., Navrátil, J., Peltanová, B., Polanska, H. H., Raudenská, M., & Masařík, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188705 · Cited by 91
Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
van Oosterwijk, J. G., Anninga, J., Gelderblom, H. A. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.07.012 · Cited by 90
Friend or foe—IDH1 mutations in glioma 10 years on
Huang, L. E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz134 · Cited by 90
“Accordingly, exogenous IDH1R132H has been shown to increase anchorage-independent growth of immortalized human astrocytes compared with wild-type control (34,42,60,70,71) (Table 3).”
BackgroundInfluentialPrognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Xia, L., Wu, B., Fu, Z., Fěng, F., Qiao, E., Li, Q., Sun, C., & Ge, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4008 · Cited by 86
“Studies have shown that 2-HG is equivalent to α-ketoglutarate in structure, and competitively suppresses the activity of dioxygenases [69].”
BackgroundCell-Autonomous Metabolic Reprogramming in Hypoxia
Schito, L., & Rey, S. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.006 · Cited by 88
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases
Tarhonskaya, H., Rydzik, A. M., Leung, I. K. H., Loik, N. D., Chan, M. C., Kawamura, A., McCullagh, J. S. O., Claridge, T. D. W., Flashman, E., & Schofield, C. J. (2014) · Nature Communications · doi:10.1038/ncomms4423 · Cited by 80
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 84
Nakagawa, M., Nakatani, F., Matsunaga, H., Seki, T., Endo, M., Ogawara, Y., Machida, Y., Katsumoto, T., Yamagata, K., Hattori, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0929-9 · Cited by 79
Fathi, A. T., Sadrzadeh, H., Comander, A. H., Higgins, M. J., Bardia, A., Perry, A. M., Burke, M. E., Silver, R. M., Matulis, C. R., Straley, K. S., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0417 · Cited by 79
Durán, R. V., & Hall, M. N. (2012) · Cell Cycle · doi:10.4161/cc.22632 · Cited by 77
Elhammali, A., Ippolito, J. E., Collins, L., Crowley, J., Marasa, J., & Piwnica-Worms, D. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0572 · Cited by 77
“In addition, mutant IDH1 was recently shown to promote soft agar colony formation of immortalized human astrocytes (14).”
BackgroundOH, the Places You’ll Go! Hydroxylation, Gene Expression, and Cancer
Ploumakis, A., & Coleman, M. L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.026 · Cited by 81
“Consistent with TET enzymes being targets of D-2HG (Figueroa et al., 2010; Koivunen et al., 2012; Xu et al., 2011), IDH and TET2 mutations are mutually exclusive (Figueroa et al., 2010; Gaidzik et al., 2012), and DNA from IDH mutant tumors is frequently hypermethylated (Ko et al., 2010; Turcan et…”
BackgroundBecker-Kettern, J., Paczia, N., Conrotte, J.-F., Kay, D. P., Guignard, C., Jung, P. P., & Linster, C. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.704494 · Cited by 75
“Although some mechanisms have been proposed by which D-2HG could stimulate tumor progression (activation of the prolyl 4-hydroxylase EGLN that acts on HIF (75) and inhibition of DNA and histone demethylation (76, 77)), the better outcome of glioma patients with IDH mutations compared with glioma patients without IDH m…”
Koivunen, P., & Laukka, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2721-8 · Cited by 82
“a [15] b [60] c [83] d Ki value e [59] f [92] g [93] h [54] i [94] Fumarate (μM) Succinate (μM) R-2-hydroxyglutarate (μM) S-2-hydroxyglutarate (μM) Citrate (μM)”
BackgroundSelf-citationAn Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
Shirai, Y., Chow, C. C. T., Kambe, G., Suwa, T., Kobayashi, M., Takahashi, I., Harada, H., & Nam, J. (2021) · Cancers · doi:10.3390/cancers13112813 · Cited by 79
EglN2 associates with the NRF 1‐ PGC 1α complex and controls mitochondrial function in breast cancer
Zhang, J., Wang, C., Chen, X., Takada, M., Fan, C., Zheng, X., Wen, H., Liu, Y., Wang, C., Pestell, R. G., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591437 · Cited by 72
“…was digested with BamHI and EcoRI and cloned into the pBABE-puro vector cut with these two enzymes. pLenti6 FLAG-EglN2 was described previously (Koivunen et al , 2012). pSG5-TETr-EglN2 fusion was created by ligating the full-length EglN2 ORF (amplified with 5 0 BamHI site and 3 0 EcoRI site)…”
Cardioprotection by nicotinamide mononucleotide (NMN): Involvement of glycolysis and acidic pH
Nadtochiy, S. M., Wang, Y. T., Nehrke, K. W., Munger, J., & Brookes, P. S. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.06.007 · Cited by 77
“2-HG is a competitive inhibitor of the α-ketoglutarate dependent dioxygenase family of epigenetic regulators, which includes the JmjC domain-containing histone demethylases, the TET 5-methylcytosine hydroxylases and the EGLN prolylhydroxylases that regulate hypoxia inducible factor (HIF) [38,39].”
BackgroundInfluentialMetabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 73
Kurek, K. C., Pansuriya, T. C., van Ruler, M. A. J. H., van den Akker, B., Luks, V. L., Verbeke, S., Kozakewich, H. P., Sciot, R., Lev, D. C., Lazar, A. J., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.012 · Cited by 73
Attacking the supply wagons to starve cancer cells to death
Selwan, E. M., Finicle, B. T., Kim, S. M., & Edinger, A. L. (2016) · FEBS Letters · doi:10.1002/1873-3468.12121 · Cited by 69
“As metabolic reprogramming regulates stem cell fate and differentiation, CSCs might be forced to differentiate by metabolic therapies. α -ketoglutarate can maintain the undifferentiated state of embryonic stem cells in vitro [207], and alterations in metabolism can block differentiation [208].”
BackgroundKalinina, J., Ahn, J. Y., Devi, N. S., Wang, L., Li, Y., Olson, J. J., Glantz, M., Smith, T. W., Kim, E. L., Giese, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2965 · Cited by 73
Biology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 74
“Studies differ, however, on whether the effect is inhibitory, as with other αKG- dependent dioxygenases,[70] or stimulatory, involving EGLN- catalyzed conversion of (R)2HG back to αKG and its use as a cosubstrate for subsequent HIF hydroxylation (range 210– 300 μM IC50) [71] (Figures 1 and 2).”
BackgroundInfluentialKhurshed, M., Molenaar, R. J., Lenting, K., Leenders, W. P. J., & Noorden, C. J. F. V. (2017) · Oncotarget · doi:10.18632/oncotarget.17106 · Cited by 75
“IDH1/2MUT changes cellular metabolism via 4 mechanisms: 1) loss of wild-type IDH1/2 (IDH1/2WT) function that affects carbohydrate and NADP+/NADPH metabolism; 2) accumulation of D-2HG that further restricts the activity of various enzymes such as α-ketoglutarate dehydrogenase (α-KGDH), succinate dehydrogenase (SDH) and…”
BackgroundIsocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
Liu, S., Cadoux-Hudson, T. A. D., & Schofield, C. J. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.012 · Cited by 74
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Nassereddine, S., Lap, C. J. G., Haroun, F., & Tabbara, I. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3161-0 · Cited by 72
Wang, X., Peng, H., Yang, L., You, F., Teng, F., Hou, L., & Wolfbeis, O. S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405048 · Cited by 74
Hypoxic Regulation of Gene Transcription and Chromatin: Cause and Effect
Kindrick, J. D., & Mole, D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218320 · Cited by 71
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 87
“Consistent with this, PHD2 depletion in erythroleukemic cells transformed by the expression of IDH1 mutant abolished their growth factor independence and restored normal differentiation.(104,105) ROS has also been assigned a role in regulating PHD activity.”
BackgroundNatsumeda, M., Igarashi, H., Nomura, T., Ogura, R., Tsukamoto, Y., Kobayashi, T., Aoki, H., Okamoto, K., Kakita, A., Takahashi, H., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0158-y · Cited by 68
“A recent report has shown the stimulation of HIF prolyl hydroxylases by (R) enantiomer of 2HG in mutant IDH immortalized astrocytes leads to a reduced level of HIF, but enhanced proliferation [29].”
Leather, T., Jenkinson, M. D., Das, K., & Poptani, H. (2017) · Metabolites · doi:10.3390/metabo7020029 · Cited by 71
“Activation of these enzymes facilitates the ubiquitination and proteasomal degradation of hypoxia inducible factor, a process that has been shown to enhance the proliferation of astrocytes in culture [20].”
BackgroundZhang, M., Gao, C., Guo, X., Guo, S., Kang, Z., Xiao, D., Yan, J., Tao, F., Zhang, W., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04513-0 · Cited by 72
Henze, A.-T., Garvalov, B. K., Seidel, S., Cuesta, A. M., Ritter, M., Filatova, A., Foss, F., Dopeso, H., Essmann, C. L., Maxwell, P. H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6582 · Cited by 68
Highly selective recognition and ultrasensitive quantification of enantiomers
Xu, L., Xu, Z., Ma, W., Liu, L., Wang, L., Kuang, H., & Xu, C. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20692k · Cited by 65
Zhang, L., Liu, Y., Wang, M., Wu, Z., Li, N., Zhang, J., & Yang, C. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx056 · Cited by 68
Glutarate regulates T cell metabolism and anti-tumour immunity
Minogue, E., Cunha, P. P., Wadsworth, B. J., Grice, G. L., Sah‐Teli, S. K., Hughes, R., Bargiela, D., Quaranta, A., Zurita, J., Antrobus, R., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00855-2 · Cited by 67
Self-citationA metabolic signature for long life in the C aenorhabditis elegans M it mutants
Butler, J. A., Mishur, R. J., Bhaskaran, S., & Rea, S. L. (2012) · Aging Cell · doi:10.1111/acel.12029 · Cited by 71
“These so-called oncometabolites are thought to act by disrupting hypoxia-inducible factor 1 (HIF-1) and/or the epigenetic landscape of cells; specifically by altering the activity of EGL-9/PHD1-3 prolyl hydroxylases (Koivunen et al. 2012), jmjC-type histone demethylases and/or TET family 5-methylcytosine (5mC) hydroxy…”
BackgroundLaukka, T., Myllykoski, M., Looper, R. E., & Koivunen, P. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.048 · Cited by 61
Self-citationGlycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness
Tiwari, V., Daoud, E. V., Hatanpaa, K. J., Gao, A., Zhang, S., An, Z., Ganji, S., Raisanen, J. M., Lewis, C. M., Askari, P., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa034 · Cited by 66
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Solomou, G., Finch, A., Asghar, A., & Bardella, C. (2023) · Cancers · doi:10.3390/cancers15112883 · Cited by 68
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 66
“However, ROS production was not found to be significantly altered in IDH1 mutant cell lines [62], and ROS levels were actually reduced in the brains of IDH1 R132H knockin NestinCre mice, although the intracellular NADP:NADPH ratio and glutathione levels were increased and decreased, respectively [60].”
BackgroundPHD3 regulates EGFR internalization and signalling in tumours
Garvalov, B. K., Foss, F., Henze, A.-T., Bethani, I., Gräf-Höchst, S., Singh, D., Filatova, A., Dopeso, H., Seidel, S., Damm, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6577 · Cited by 64
MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma
Mucaj, V, Lee, S. S., Skuli, N., Giannoukos, D. N., Qiu, B., Eisinger-Mathason, T. S. K., Nakazawa, M. S., Shay, J. E. S., Gopal, P. P., Venneti, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.168 · Cited by 61
“We defined the HIF signature by using previously - established HIF regulated genes (15).”
BackgroundMethodInfluentialSelf-citationReporter Ligand NMR Screening Method for 2-Oxoglutarate Oxygenase Inhibitors
Leung, I. K. H., Demetriades, M., Hardy, A., Lejeune, C., Smart, T. J., Szöllössi, A., Kawamura, A., Schofield, C. J., & Claridge, T. D. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301583m · Cited by 67
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases
Zurlo, G., Guo, J., Takada, M., Wei, W., & Zhang, Q. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.004 · Cited by 61
“However, some other findings demonstrated that the (R)-enantiomer of 2HG, opposing to (S)-2HG, can largely stimulate PHD/EglN activities, diminish HIF-α levels, and contribute to the proliferation of human glioma and leukemia cells, therefore demonstrating that HIF-α functions as a tumor suppressor in the tissue-conte…”
BackgroundNavis, A. C., Niclou, S. P., Fack, F., Stieber, D., van Lith, S. A. M., Verrijp, K. N., Wright, A. J., Stauber, J., Tops, B. B. J., Otte‐Höller, I., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-18 · Cited by 64
“The absence of these HIF1α-regulated hypoxia markers is in accordance with recent studies that show an inhibition of HIF1α expression induced by D2HG and EGLN in IDH1-mutant tumor cells [33,34].”
Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions
Bargiela, D., Burr, S. P., & Chinnery, P. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.02.002 · Cited by 60
Machida, Y., Nakagawa, M., Matsunaga, H., Yamaguchi, M., Ogawara, Y., Shima, Y., Yamagata, K., Katsumoto, T., Hattori, A., Itoh, M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1349 · Cited by 62
Parma, B., Wurdak, H., & Ceppi, P. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100888 · Cited by 64
“2-HG is also associated with chromatin modifications, which are potent inhibitors of α-ketoglutarate-dependent demethylases; however, in contrast to succinate and fumarate, it decreases HIF-1α levels, favoring mitochondrial metabolism (Chowdhury et al., 2011; Koivunen et al., 2012).”
BackgroundFrom genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 67
“Koi-vunen et al. 44 showed that expression of IDH1-R132H in the same immortalized human astrocyte model system 84 used in the study by Turcan et al. 87 led to more colonies formed in soft agar.”
MethodCellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target
Gargini, R., Segura‐Collar, B., & Gómez, P. S. (2020) · Cancers · doi:10.3390/cancers12061622 · Cited by 64
“Besides, 2-HG can inhibit hypoxia inducible factor 1, subunit alpha (HIF1α) signaling through the stimulation of prolyl-hydroxylases such as EGLN (egl-9 family hypoxia inducible factor 1) [47].”
BackgroundWilliams, N. C., Ryan, D. G., Costa, A. S. H., Mills, E. L., Jedrychowski, M. P., Cloonan, S. M., Frezza, C., & O'Neill, L. A. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101501 · Cited by 65
“Both D-2HG and L-2HG have been shown to act as competitive inhibitors of multiple αKG-dependent dioxygenases, including the ten-eleven translocation (TET) family of DNA hydroxylases, the Jmjj-domain containing histone lysine demethylases (KDMs), and the HIF prolyl hydroxylases (PHDs), where L-2HG has been shown to be…”
BackgroundMethodThe multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation
Strocchi, S., Reggiani, F., Gobbi, G., Ciarrocchi, A., & Sancisi, V. (2022) · Oncogene · doi:10.1038/s41388-022-02378-8 · Cited by 61
Epigenetic alterations in hematopoietic malignancies
Chung, Y. R., Schatoff, E. M., & Abdel-Wahab, O. I. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1181-z · Cited by 66
“Notably, two recent reports found that the (R)–enantiomer of 2-HG [(R)-2HG] may actually serve as a cofactor for the activation of the EGLN family of prolyl hydroxylases [120, 121].”
BackgroundIsocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma
Agnihotri, S., Aldape, K., & Zadeh, G. M. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14505 · Cited by 63
Hypoxia signaling during acute lung injury
Vohwinkel, C. U., Hoegl, S., & Eltzschig, H. K. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00226.2015 · Cited by 61
“Importantly, previous studies from the cancer field had suggested that normoxic stabilization of HIFs in cancers involves the inhibition or mutation of the metabolic enzyme SDH (43, 44, 60).”
BackgroundInfluentialOgawara, Y., Katsumoto, T., Aikawa, Y., Shima, Y., Kagiyama, Y., Soga, T., Matsunaga, H., Seki, T., Araki, K., & Kitabayashi, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2200 · Cited by 58
“Mutant IDHs increasedproliferation and represseddifferentiation in vitro cultured cells (12, 15).”
BackgroundOncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer
Lanzetti, L. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01402-6 · Cited by 65
“Although D-2HG inhibits α -KGDDs of the TET and KDM families (as mentioned above), it stimulates the activity of PHDs, thereby blunting HIF α -mediated responses [80].”
5-Hydroxymethylcytosine Profiling as an Indicator of Cellular State
Laird, A., Thomson, J. P., Harrison, D. J., & Meehan, R. R. (2013) · Epigenomics · doi:10.2217/epi.13.69 · Cited by 62
The Acidic Brain—Glycolytic Switch in the Microenvironment of Malignant Glioma
Reuss, A. M., Groos, D., Buchfelder, M., & Savaskan, N. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115518 · Cited by 60
Gunn, K., Myllykoski, M., Cao, J. Z., Ahmed, M., Huang, B., Rouaisnel, B., Diplas, B. H., Levitt, M. M., Looper, R., Doench, J. G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0825 · Cited by 60
Self-citationZhang, C., Liu, Q., Li, M., Lin, S., Peng, Y., Wu, D., Li, T. Y., Fu, Q., Jia, W., Wang, X., et al. (2015) · Cell Research · doi:10.1038/cr.2015.90 · Cited by 60
Metabolic intermediates – Cellular messengers talking to chromatin modifiers
Nieborak, A., & Schneider, R. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.01.007 · Cited by 60
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
Reiter–Brennan, C., Semmler, L., & Klein, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.82642 · Cited by 63
“[19] obtained similar results as the papers mentioned above in regard to L-2-HG, as they observed that L-2-HG inhibited prolyl hydroxylase.”
BackgroundResultInfluentialMTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation
Hansen, L. J., Sun, R., Yang, R. R., Singh, S. X., Chen, L. H., Pirozzi, C. J., Moure, C. J., Hemphill, C., Carpenter, A. B., Healy, P. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1010 · Cited by 57
“This study thus provides a new example supporting the emerging concept of aberrantmetabolism-induced epigenetic alterations in tumor cells (48, 49) and highlights the possibility of yet other metabolic alterations contributing to aberrant epigenetic regulation as previously speculated (50).”
BackgroundSelf-citationGlutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 62
Epigenetic alterations in acute myeloid leukemias
Mehdipour, P., Santoro, F., & Minucci, S. (2014) · FEBS Journal · doi:10.1111/febs.13142 · Cited by 67
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Grassian, A. R., Pagliarini, R. A., & Chiang, D. Y. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000050 · Cited by 58
Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
Hypoxic Signalling in Tumour Stroma
Laitala, A., & Erler, J. T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00189 · Cited by 58
“Other types of IDH mutations lead to the production of 2-hydroxyglutarate (2-HG), which can competitively inhibit PHDs or even increase the activity depending on the 2-HG stereoisomerism (51, 52).”
BackgroundShedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
Läsche, M., Emons, G., & Gründker, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00409 · Cited by 57
“In contrast, 2-hydroxyglutarate modulates the α-ketoglutarate-dependent activity of prolyl hydroxylases 1 and 2 (PHD1, 2) and the following hypoxiainducible factor subunit 1α (HIF-1α) stabilization (Figure 2R), thus promoting the transformation of the developing malignancy (7, 8).”
BackgroundAntagonistic functional duality of cancer genes
Stepanenko, A. A., Vassetzky, Y. S., & KAVSAN, V. M. (2013) · Gene · doi:10.1016/j.gene.2013.07.047 · Cited by 59
“HIF1 Hypoxia inducible factor 1, basic helix–loop–helix transcription factor, a master regulator of cellular response to hypoxia Koivunen et al. (2012)”
Fandrey, J., Schödel, J., Eckardt, K., Katschinski, D. M., & Wenger, R. H. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02334-8 · Cited by 60
The role of mitochondria in the oncogenic signal transduction
Frezza, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.013 · Cited by 57
Alterations of 5-Hydroxymethylcytosine in Human Cancers
Mariani, C. J., Madžo, J., Moen, E. L., Yesilkanal, A. E., & Godley, L. A. (2013) · Cancers · doi:10.3390/cancers5030786 · Cited by 57
The role of PHD2 mutations in the pathogenesis of erythrocytosis
Gardie, B., Percy, M. J., Hoogewijs, D., Chowdhury, R., Bento, C., McMullin, M. F., Schofield, C. J., Lee, F. S., Richard, S., Arsenault, P. R., et al. (2014) · Hypoxia · doi:10.2147/hp.s54455 · Cited by 55
“biochemical studies have revealed it is a weak PHD inhibitor(80) and, in some studies, even a PHD activator.(81) Germline”
Protein lysine acetylation guards metabolic homeostasis to fight against cancer
Xu, W., Li, Y., LIU, C., & Zhao, S. (2013) · Oncogene · doi:10.1038/onc.2013.163 · Cited by 58
Altered Hypoxic–Adenosine Axis and Metabolism in Group III Pulmonary Hypertension
Garcia‐Morales, L. J., Chen, N., Weng, T., Luo, F., Davies, J., Philip, K., Volcik, K. A., Melicoff, E., Amione‐Guerra, J., Bunge, R. R., et al. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0145oc · Cited by 54
Metadata
- Authors
- Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., Verhaak, R. G. W., Yan, H., & Kaelin Jr, W. G.
- Affiliations
- University of Oulu (FI)
- Brigham and Women's Hospital (US)
- Duke University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Calgary (CA)
- University of Utah (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 484-488
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656605
- OpenAlex
- W2142898716
- Cited by
- 727
- References
- 41
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 32 · 2022: 35 · 2021: 44 · 2020: 56 · 2019: 52 · 2018: 66 · 2017: 63 · 2016: 61 · 2015: 57 · 2014: 70 · 2013: 59 · 2012: 43
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA140316)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- R-enantiomer, IDH1 mutation, IDH2 mutation, hypoxia-inducible factor, glioma, astrocyte proliferation, oncometabolites, cancer metabolism, histone demethylation, DNA hypermethylation, CpG island methylator phenotype
- MeSH terms
- Astrocytes, Cell Line, Cell Transformation, Neoplastic, Enzyme Activation, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Nuclear Proteins, Oncogenes, Procollagen-Proline Dioxygenase, Cell Line, Tumor, Cell Proliferation, Dioxygenases, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.